Atorvastatin in stroke: a review of SPARCL and subgroup analysis

Review

(3517) Views  (1539) Full article downloads

Authors: Branko N Huisa, Andrew B Stemer, Justin A Zivin

Published Date March 2010 Volume 2010:6 Pages 229 - 236

DOI: http://dx.doi.org/10.2147/VHRM.S6795

Branko N Huisa, Andrew B Stemer, Justin A Zivin

Department of Neuroscience University of California, San Diego, CA, USA

Abstract: Statin therapy in patients with cardiovascular disease is associated with reduced incidence of stroke. The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transient ischemic attack (TIA) reduced the incidence of fatal or nonfatal stroke by 16%. Several post hoc analyses of different subgroups followed the SPARCL study. They have not revealed any significant differences when patients were sorted by age, sex, presence of carotid disease or type of stroke, with the exception of intracranial hemorrhage as the entry event. Lower low-density lipoprotein cholesterol levels in addition to possible neuroprotective mechanisms due to atorvastatin treatment correlate with improved risk reduction. Although not predefined subgroups and subject to an insufficient power, these post hoc studies have generated new clinical questions. However, clinicians should avoid denying therapy based on such subgroup analysis. At this point, the best evidence powerfully demonstrates stroke and TIA patients should be prescribed high dose statin therapy for secondary stroke prevention.

Keywords: statins, intracranial hemorrhage, neuroprotection, outcome, prevention, carotid stenosis, transient ischemic attack

Readers of this article also read: